Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Plain-language summary
This trial is testing chidamide (HDAC inhibitor) combined with azacitidine and other agents for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
golidocitinib with azacytidine and chidamide (DRUG): In Phase I, a "3+3" dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD). In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma
golidocitinib with azacytidine and chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details